Alpha Cognition Inc (TSE:ACOG) has released an update.
Alpha Cognition Inc., a biopharmaceutical firm focusing on neurodegenerative disorders, has had its resale registration statement declared effective by the SEC. This allows for the resale of common shares from private placements completed in 2023 and early 2024, turning the company into a reporting issuer in the US. However, Alpha Cognition will not be selling any new securities or receiving proceeds from the sales under this registration.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
